Market Size and Forecast
The antithrombin market reached a value of USD 0.93 billion in 2025 and is expected to rise to USD 1.44 billion by 2034, growing at a CAGR of 4.94% between 2026 and 2034. This growth is driven by rising cases of blood clotting disorders, growing use of antithrombin in surgeries and therapies, and increasing research activities in biotechnology. Advancements in protein purification and plasma-derived products also contribute to the steady expansion of this market.
According to Value Market Research, the report provides a detailed view of the market’s size, structure, and future growth patterns. It highlights innovation in biologics, expansion in therapeutic applications, and strategic moves by companies shaping the antithrombin landscape.
Market Segmentation
The market is categorized by technology application, source, and dosage form. Each segment contributes to the understanding of how antithrombin is produced, processed, and used in healthcare.
By Technology Application
This segment explains the various uses of antithrombin across medical and research applications.
• Therapeutics: Used in treating coagulation disorders and preventing thrombosis during surgeries and pregnancies.
• Research: Supports scientific studies for drug development and genetic engineering.
• Diagnostics: Helps in laboratory testing for clotting deficiencies and related conditions.
By Source
This category identifies the origins of antithrombin used for medical and research purposes.
• Human: Derived from plasma and widely used for safe, clinical-grade therapies.
• Goat Milk: Produced through recombinant DNA technology offering scalable production.
• Others: Includes synthetic and alternative biological sources for research purposes.
By Dosage Form
This segment describes how antithrombin products are formulated for use.
• Lyophilized: Freeze-dried powders that offer longer shelf life and easy transportation.
• Liquid: Ready-to-use formulations preferred for immediate therapeutic applications.
Key Players
The antithrombin market is moderately competitive with both established biopharmaceutical firms and emerging biotechnology companies focusing on quality and innovation.
- Grifols S.A.: A global healthcare company producing plasma-derived medicines and biologics.
• Octapharma AG: Specializes in human protein products and plasma-based therapies.
• LFB USA: Focuses on biopharmaceuticals for treating immune and coagulation disorders.
• CSL: Develops plasma therapies and recombinant biotherapies addressing clotting issues.
• Takeda Pharmaceutical Company Limited: Offers innovative antithrombin formulations and research-based therapies.
Companies are investing in research, strategic collaborations, and advanced manufacturing to improve product availability and therapeutic effectiveness.
Regional Insights
The global antithrombin market is expanding steadily across all major regions, supported by healthcare investments and research progress.
- North America: Leads with strong biotechnology infrastructure, advanced diagnostics, and high awareness of thrombotic disorders.
• Europe: Holds a significant share due to government support for rare disease treatment and strong clinical research presence.
• Asia-Pacific: Expected to grow rapidly with rising healthcare spending and expansion of biopharma manufacturing capabilities.
• Latin America: Shows moderate growth driven by improving access to plasma-derived medicines.
• Middle East & Africa: Emerging demand supported by rising awareness and hospital modernization.
Information Source: https://www.valuemarketresearch.com/report/antithrombin-market